Phase II trial of i.v. vinorelbine and cisplatin in inoperable locally advanced or disseminated non-small-cell lung cancer: The South African experience

Current Medical Research and Opinion

Volumn 15, Issue 3, 1999, Pages 185-192

  Goedhals, L ^a   Vorobiof, D A ^b,f   Bezwoda, W ^f   Van Merwe, A ^c   Jordaan, J P ^d   Barnardt, P ^e   Smith, B L ^a  

^a National Hospital Bloemfontein   (South Africa)

^b Sandton Oncology Centre   (South Africa)

^c Private Centre   (South Africa)

^d ADDINGTON HOSPITAL   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f P O Box 2059 ^*

Author keywords

Cisplatin; Non small cell lung cancer; One year survival; Overall response rate; Phase II study; Vinorelbine

Indexed keywords

ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SOUTH AFRICA; VOMITING;

EID: 0032873966     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909114090     Document Type: Article

References (25)

1. Parkin, D. M. (1993). Estimates of the worldwide incidence of eighteen major cancer in 1985. Int. J. Cancer, 54, 594-606.
2. Standing Medical Advisory Committee Report on Working Party (chaired by Whitehouse, J. M. A.) (1994). Management of lung cancer - current clinical practices. ICRU, Bethesda, p. 18.
3. Ginsberg, R. J., Kris, M. G., Armstrong, J. G. (1993). Cancer of the lung. In de Vita, V. T. Jr. et al. (Eds): Cancer: Principles and Practice of Oncology. Lippincott, Philadelphia, 4th edn, pp. 673-758.
4. Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer, a meta analysis using updated data in individual patients from 52 randomized trials. Brit. Med. J., 311, 899-909.
5. Rapp, E., Pater, J. L., Willan, A. et al. (1988). Chemotherapy can prolong survival in patients with advanced non small cell lung cancer. Report of a Canadian multicenter randomized trial. J. Clin. Oncol., 6, 633-641.
6. Jaakkimainen, L., Goodwin, P. J., Pater, J. et al. (1990). Counting the cost of chemotherapy in the National Cancer Institute of Canada randomized trial in non small cell lung cancer. J. Clin. Oncol., 8, 1301-1309.
7. Depierre, A., Lemarie, E., Dabouis, G. et al. (1991). A phase II study of Vinorelbine (vinorelbine) in the treatment of non small cell lung cancer. Am. J. Clin. Oncol., 14, 115-119, 1991.
8. Crawford, J., O'Rourke, M., Schiller J. et al. (1996). Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non small cell lung cancer. J. Clin. Oncol., 14, 2774-2784.
9. Le Chevalier, T., Brisgand, D., Douillard, J. Y. et al. (1994). Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non small cell lung cancer. Results of a European multicenter trial including 612 patients. J. Clin. Oncol., 12, 360-367.
10. Wozniak, A. J., Crowley, J. J., Balcerzak, S. P. et al. (1998). Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer. A Southwest Oncology Group Study. J. Clin. Oncol., 16, 2459-2465.
11. Panettiere, F. J., Vance, R. B. and Stuckey, W. J. (1983). Evaluation of a single agent cisplatin in the management of non-small cell carcinoma of the lung. A Southwest Oncology Group study. Cancer Treat. Rep., 67, 399-400.
12. Gandara, D. R., Crowly, J., Livingston, R. B. et al. (1993). Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer. A phase III study of the Southwest Oncology Group. J. Clin. Oncol., 11, 873-878.
13. Klastersky, J. P., Schulier, G., Bureau, P. et al. (1989). Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J. Clin. Oncol., 7, 1087-1092.
14. Anderson, H., Lund, B. Bach, F. et al. (1994). Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer. A phase II study. J. Clin. Oncol., 9, 1821-1826.
15. Abratt, R. P., Bezwoda, W. R., Goedhals, L. et al. (1997). Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J. Clin. Onocol., 15, 744-749.
16. Shepherd, F. A., Cormier, Y., Burkes, R. et al. (1997). Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Seminars in Oncology, 24 (Suppl 8), S8-27-S8-30.
17. Lopez Cabrenzo, M. P., Cardenal, F., Artal, A. et al. (1997). Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer. A randomized trial by the Spanish lung cancer group. IASLC, Abstract 27.
18. Crino, L., Conte, P., De Marins, F. et al. (1998). A randomised trial of gemcitabine cisplatin (GP) versus mitomycin ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proc. ASCO, Abstract 1750.
19. Millward, M. J., Bishop, J. F., Friedlander, M. et al. (1996). Phase II trial of a three hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol., 14, 142-148.
20. Alberto, V., Rosell, R., Gonzalez-Larriba, J. L. et al. (1995). Single agent Taxol, three hour infusion, in untreated advanced non-small cell lung cancer. Ann. Oncol., 6, Suppl. S49-S52.
21. Von Pawel, J., Wagner, H., Niederle, N. et al. (1996). Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Sem. Oncol., 23 (Suppl 16), 47-50.
22. Perol, M., Souquet, P. J., Riou, R. et al. (1997). Preliminary results of a phase II study with taxol (paclitaxel) and cisplatin in advanced non-small cell lung cancer (NSCLC). IASLC, Abstract 128.
23. Russell, F. D., Madan, J. and David, H. J. (1997). Paclitaxel by either 1 hour or 24 hour infusion in combination with carboplatin in advanced non-small cell lung cancer, preliminary results comparing sequential phase II trials. Sem. Oncol., 24, S12-27-S12-29.
24. Gatzmeir, U., Von Pawel, J., Gottfried, M. et al. (1998). Phase III comparative study of high dose cisplatin (HD, cis) versus a combination of paclitaxel (Tax) and cisplatin (Cis) in patients with advanced non-small cell lung cancer (NSCLC). Proc. ASCO, Abstract 1748.
25. Ginsberg, R. J., Vokes, E. E. and Raben, A. (1997). Cancer of the lung. In de Vita, V. T. Jr. et al. (Eds): Cancer: Principles and Practice of Oncology. Chapter 30, Lippincott, Philadelphia, 5th edn.